Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04135352
Title A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

head and neck squamous cell carcinoma

skin melanoma

Therapies

Pembrolizumab + V938

Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0002) San Francisco California 94158 United States Details
MD Anderson Cancer Center ( Site 0001) Houston Texas 77030 United States Details
Huntsman Cancer Institute ( Site 0004) Salt Lake City Utah 84112 United States Details
Princess Margaret Cancer Centre ( Site 0010) Toronto Ontario M5G 2M9 Canada Details
Rambam Health Care Campus-Oncology Division ( Site 0020) Haifa 3109601 Israel Details
Chaim Sheba Medical Center ( Site 0021) Ramat Gan 5265601 Israel Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field